secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001437749-25-000109
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton acquires Galzin (zinc acetate) for $7.2M; rare disease product for Wilson Disease
--------------------------------------------------------------------------------

- Acquired Galzin from Teva Pharmaceuticals for $7.0M at closing plus $0.2M for inventory.
- Will pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of first commercial sale.
- Galzin is the only FDA-approved zinc maintenance therapy for Wilson Disease; <5,000 U.S. patients.
- Eton expects to assume U.S. commercialization in Q1 2025 with its metabolic sales force.
- Also acquired European rights; third party commercializes under Wilzin with Eton supplying product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925000109/0001437749-25-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925000109/eton20241219_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer